Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
COYA
#3330
Coya Therapeutics, Inc. Common Stock
4.9
6
+1.22%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+1.22%
Monatliche Änderung
+2.06%
6 month change
-25.30%
Jahresänderung
-24.04%
Vorheriger Schlusskurs
4.9
0
Open
4.9
6
Bid
Ask
Low
4.9
6
High
4.9
6
Volumen
2
Märkte
Aktien
Gesundheitswesen
COYA
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Dividends per share
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
Nachrichten
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock with $18 target
Coya Therapeutics secures $11.1 million in private placement
Coya Therapeutics advances ALS and FTD clinical trials in 2026
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18
Tracking David Einhorn’s Greenlight Capital Portfolio – Q3 2025 Update (NYSE:GRBK)
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock
H.C. Wainwright reaffirms Buy rating on Coya Therapeutics stock at $18 target
Coya Therapeutics closes $23 million public offering of common stock
Coya Therapeutics stock falls after pricing $20 million public offering
Coya Therapeutics prices $20 million public offering of common stock
Coya Therapeutics announces common stock offering to fund operations
Why David Einhorn’s Greenlight prefers this tiny biotech over AI ‘excitement’